SG11202000730QA - Compositions and methods for treating galactosemia - Google Patents
Compositions and methods for treating galactosemiaInfo
- Publication number
- SG11202000730QA SG11202000730QA SG11202000730QA SG11202000730QA SG11202000730QA SG 11202000730Q A SG11202000730Q A SG 11202000730QA SG 11202000730Q A SG11202000730Q A SG 11202000730QA SG 11202000730Q A SG11202000730Q A SG 11202000730QA SG 11202000730Q A SG11202000730Q A SG 11202000730QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- galactosemia
- treating
- treating galactosemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538443P | 2017-07-28 | 2017-07-28 | |
| PCT/US2018/044199 WO2019023648A1 (en) | 2017-07-28 | 2018-07-27 | Compositions and methods for treating galactosemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000730QA true SG11202000730QA (en) | 2020-02-27 |
Family
ID=65039851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000730QA SG11202000730QA (en) | 2017-07-28 | 2018-07-27 | Compositions and methods for treating galactosemia |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11590131B2 (en) |
| EP (2) | EP3658142B1 (en) |
| JP (2) | JP7307059B2 (en) |
| AU (2) | AU2018307964B2 (en) |
| BR (1) | BR112020001755A2 (en) |
| CA (1) | CA3071114A1 (en) |
| DK (1) | DK3658142T3 (en) |
| FI (1) | FI3658142T3 (en) |
| HR (1) | HRP20240840T1 (en) |
| HU (1) | HUE067079T2 (en) |
| IL (1) | IL272246A (en) |
| LT (1) | LT3658142T (en) |
| MX (2) | MX2020001057A (en) |
| PL (1) | PL3658142T3 (en) |
| PT (1) | PT3658142T (en) |
| RU (1) | RU2020107188A (en) |
| SG (1) | SG11202000730QA (en) |
| SI (1) | SI3658142T1 (en) |
| WO (1) | WO2019023648A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018307964B2 (en) * | 2017-07-28 | 2023-11-16 | Applied Therapeutics Inc. | Compositions and methods for treating galactosemia |
| WO2020173495A1 (en) * | 2019-02-28 | 2020-09-03 | 石药集团中奇制药技术（石家庄）有限公司 | Salt of aldose reductase inhibitor, and preparation method and application thereof |
| BR112021019596A2 (en) * | 2019-04-01 | 2021-11-30 | Applied Therapeutics Inc | Aldose reductase inhibitors |
| JP2022531466A (en) | 2019-05-07 | 2022-07-06 | ユニバーシティ オブ マイアミ | Treatment and detection of hereditary neuropathy and related disorders |
| EP4041219A4 (en) * | 2019-10-08 | 2023-11-01 | Applied Therapeutics, Inc. | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency |
| CN115996725A (en) * | 2020-05-01 | 2023-04-21 | 应用治疗公司 | Aldose reductase inhibitors for the treatment of sorbitol dehydrogenase deficiency |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0189272A3 (en) | 1985-01-17 | 1987-08-19 | Fujisawa Pharmaceutical Co., Ltd. | New furanone derivatives, processes for preparation thereof and use thereof |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| IL80475A (en) | 1985-11-07 | 1993-01-31 | Pfizer | Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them |
| CA1299178C (en) * | 1985-11-07 | 1992-04-21 | Banavara Lakshmana Mylari | Heterocyclic oxophtalazinyl acetic acids |
| AU7386887A (en) | 1986-06-12 | 1987-12-17 | American Home Products Corporation | Method of stimulating the immune system with tolrestat;(n-((5 -(trifluoromethyl)-6-methoxy-1-naphthenyl)thioxomethyl)-n-me hylglycine) |
| US4868301A (en) | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
| CA1307537C (en) * | 1987-12-23 | 1992-09-15 | Jay E. Wrobel | N-naphthoylglycines as aldose reductase inhibitors |
| WO1989006651A1 (en) | 1988-01-19 | 1989-07-27 | Pfizer Inc. | 1h-indazole-3-acetic acids as aldose reductase inhibitors |
| US4954629A (en) | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| FR2647676A1 (en) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors |
| WO1991009019A1 (en) | 1989-12-15 | 1991-06-27 | Pfizer Inc. | Substituted oxophthalazinyl acetic acids and analogs thereof |
| JPH0495025A (en) | 1990-08-08 | 1992-03-27 | Asahi Chem Ind Co Ltd | Aldose reductase inhibitor |
| KR950703539A (en) | 1992-09-28 | 1995-09-20 | 알렌 제이. 스피겔 | SUBSTITUTED PYRIMIDINES FOR CONTROL OR DIABETIC COMPLICATIONS |
| US5464961A (en) | 1993-09-10 | 1995-11-07 | Olin Corporation | Arcjet anode |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| TW420669B (en) | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
| WO1997008126A1 (en) | 1995-08-28 | 1997-03-06 | American Home Products Corporation | Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents |
| PL179170B1 (en) | 1995-09-15 | 2000-07-31 | Inst Lekow | Novel compounds, derivatives of genistein |
| EP0776895B1 (en) | 1995-11-20 | 1998-10-14 | Eli Lilly And Company | Protein kinase C inhibitor |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| EP1017697A1 (en) | 1997-09-23 | 2000-07-12 | Novo Nordisk A/S | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| MXPA02003122A (en) | 1998-03-31 | 2004-04-21 | Inst For Pharm Discovery Inc | Substituted indolealkanoic acids. |
| EP0982306A3 (en) | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph of zopolrestat monohydrate |
| EP1185275A1 (en) | 1999-04-01 | 2002-03-13 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| JP4511655B2 (en) | 1999-08-25 | 2010-07-28 | ユニチカ株式会社 | Sorbitol dehydrogenase, microorganism producing the same, and method for producing the same |
| US6916824B1 (en) | 1999-11-12 | 2005-07-12 | Kansas State University Research Foundation | Methods of treating cataracts and diabetic retinopathy with tricyclic pyrones |
| US20020068740A1 (en) | 1999-12-07 | 2002-06-06 | Mylari Banavara L. | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| AU2002226634B2 (en) | 2001-03-30 | 2007-01-25 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| CA2473036A1 (en) | 2002-01-23 | 2003-07-31 | Paul Leslie Ornstein | Melanocortin receptor agonists |
| WO2003105864A1 (en) | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
| WO2003105845A1 (en) | 2002-06-14 | 2003-12-24 | Takeda Chemical Industries, Ltd. | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers |
| CA2814774C (en) | 2003-01-31 | 2016-03-22 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| JP5044122B2 (en) * | 2003-10-24 | 2012-10-10 | 株式会社明治 | Novel inhibitors of late glycation end product formation and aldose reductase inhibitors |
| US20070021366A1 (en) | 2004-11-19 | 2007-01-25 | Srivastava Satish K | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
| US20110092566A1 (en) | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
| WO2008124570A1 (en) | 2007-04-05 | 2008-10-16 | Morphotek, Inc. | Methods for inhibiting the binding of endosialin to ligands |
| CN101143868A (en) | 2007-09-04 | 2008-03-19 | 北京理工大学 | Aldose reductase inhibitor structure and use |
| EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| US20100215726A1 (en) | 2009-02-25 | 2010-08-26 | Peter Thomas Roth | Compositions for Diminishing the Appearance of Wrinkles |
| US20130029983A1 (en) | 2009-09-23 | 2013-01-31 | Carlo Ballatore | Aminothienopyridazine inhibitors of tau assembly |
| US9494605B2 (en) | 2009-11-20 | 2016-11-15 | Pharnext | Diagnostic tools for charcot-marie-tooth disease |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| PT3597650T (en) | 2010-07-16 | 2022-12-16 | Univ Columbia | Aldose reductase inhibitors and uses thereof |
| WO2012138384A1 (en) | 2010-11-15 | 2012-10-11 | U.S. Army Medical Research And Materiel Command | Field sampling kit and methods for collecting and detecting alkyl methylphosphonic acids |
| CN102512407B (en) | 2011-11-23 | 2014-05-21 | 中山大学 | Application of utilizing beta-phenylalanine compounds as aldose reductase inhibitors |
| WO2013123403A1 (en) | 2012-02-15 | 2013-08-22 | Sanford-Burnham Medical Research Institute | Theranostics platform and methods of use |
| GB201205739D0 (en) | 2012-03-30 | 2012-05-16 | Ucl Business Plc | Treatment of acute inflammation in the respiratory tract |
| US9921221B2 (en) | 2012-07-26 | 2018-03-20 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| US20170362237A1 (en) | 2016-06-17 | 2017-12-21 | Banavara L. Mylari | Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications |
| EP2967339B1 (en) | 2013-03-15 | 2019-11-20 | Biogen MA Inc. | Assessment of labeled probes in a subject |
| JP6187364B2 (en) | 2014-03-31 | 2017-08-30 | ブラザー工業株式会社 | Printing device |
| CN207966623U (en) | 2015-09-01 | 2018-10-12 | 株式会社村田制作所 | Coil build-in components |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| IL283809B2 (en) | 2016-06-21 | 2024-01-01 | Univ Columbia | Compounds for use in a method of treating neuropathy, retinopathy, nephropathy, or cardiomyopathy |
| WO2018090002A1 (en) | 2016-11-14 | 2018-05-17 | Memorial Sloan-Kettering Cancer Center | Stem cell derived schwann cells |
| JP7191388B2 (en) | 2017-03-23 | 2022-12-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US20200131203A1 (en) | 2017-04-27 | 2020-04-30 | Applied Therapeutics, Inc. | Aldose reductase inhibitors and uses thereof |
| AU2018307964B2 (en) * | 2017-07-28 | 2023-11-16 | Applied Therapeutics Inc. | Compositions and methods for treating galactosemia |
| US11329472B2 (en) | 2018-07-20 | 2022-05-10 | Texas Instruments Incorporated | Methods and apparatus to prevent undesired triggering of short circuit or over current protection |
| WO2020040831A1 (en) | 2018-08-20 | 2020-02-27 | Perlara Pbc | Methods for treating congenital disorders of glycosylation |
| US20220071880A1 (en) | 2019-02-12 | 2022-03-10 | Applied Therapeutics, Inc. | Methods for treating cutaneous aging |
| BR112021019596A2 (en) | 2019-04-01 | 2021-11-30 | Applied Therapeutics Inc | Aldose reductase inhibitors |
| JP2022531466A (en) | 2019-05-07 | 2022-07-06 | ユニバーシティ オブ マイアミ | Treatment and detection of hereditary neuropathy and related disorders |
| EP4041219A4 (en) | 2019-10-08 | 2023-11-01 | Applied Therapeutics, Inc. | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency |
| EP4125909A1 (en) | 2020-03-31 | 2023-02-08 | Applied Therapeutics Inc. | Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy |
| CN115996725A (en) | 2020-05-01 | 2023-04-21 | 应用治疗公司 | Aldose reductase inhibitors for the treatment of sorbitol dehydrogenase deficiency |
-
2018
- 2018-07-27 AU AU2018307964A patent/AU2018307964B2/en active Active
- 2018-07-27 HR HRP20240840TT patent/HRP20240840T1/en unknown
- 2018-07-27 DK DK18838277.4T patent/DK3658142T3/en active
- 2018-07-27 CA CA3071114A patent/CA3071114A1/en active Pending
- 2018-07-27 SG SG11202000730QA patent/SG11202000730QA/en unknown
- 2018-07-27 RU RU2020107188A patent/RU2020107188A/en unknown
- 2018-07-27 EP EP18838277.4A patent/EP3658142B1/en active Active
- 2018-07-27 WO PCT/US2018/044199 patent/WO2019023648A1/en active Application Filing
- 2018-07-27 JP JP2020527861A patent/JP7307059B2/en active Active
- 2018-07-27 SI SI201831127T patent/SI3658142T1/en unknown
- 2018-07-27 FI FIEP18838277.4T patent/FI3658142T3/en active
- 2018-07-27 MX MX2020001057A patent/MX2020001057A/en unknown
- 2018-07-27 PL PL18838277.4T patent/PL3658142T3/en unknown
- 2018-07-27 LT LTEPPCT/US2018/044199T patent/LT3658142T/en unknown
- 2018-07-27 EP EP24167651.9A patent/EP4417260A2/en active Pending
- 2018-07-27 US US16/634,509 patent/US11590131B2/en active Active
- 2018-07-27 PT PT188382774T patent/PT3658142T/en unknown
- 2018-07-27 HU HUE18838277A patent/HUE067079T2/en unknown
- 2018-07-27 BR BR112020001755-8A patent/BR112020001755A2/en unknown
-
2020
- 2020-01-26 IL IL272246A patent/IL272246A/en unknown
- 2020-01-27 MX MX2022015186A patent/MX2022015186A/en unknown
-
2022
- 2022-10-24 JP JP2022169791A patent/JP7541064B2/en active Active
-
2023
- 2023-01-23 US US18/158,089 patent/US20230346782A1/en active Pending
-
2024
- 2024-01-30 AU AU2024200537A patent/AU2024200537A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018307964A1 (en) | 2020-02-13 |
| SI3658142T1 (en) | 2024-09-30 |
| RU2020107188A3 (en) | 2022-04-13 |
| US20200230139A1 (en) | 2020-07-23 |
| US11590131B2 (en) | 2023-02-28 |
| JP2022188305A (en) | 2022-12-20 |
| PL3658142T3 (en) | 2024-08-26 |
| JP2020528938A (en) | 2020-10-01 |
| CA3071114A1 (en) | 2019-01-31 |
| PT3658142T (en) | 2024-06-27 |
| HUE067079T2 (en) | 2024-09-28 |
| EP3658142B1 (en) | 2024-04-17 |
| JP7307059B2 (en) | 2023-07-11 |
| EP3658142A1 (en) | 2020-06-03 |
| FI3658142T3 (en) | 2024-07-15 |
| MX2022015186A (en) | 2023-01-24 |
| DK3658142T3 (en) | 2024-06-24 |
| CN111065392A (en) | 2020-04-24 |
| WO2019023648A1 (en) | 2019-01-31 |
| LT3658142T (en) | 2024-07-25 |
| MX2020001057A (en) | 2020-11-24 |
| IL272246A (en) | 2020-03-31 |
| AU2024200537A1 (en) | 2024-02-15 |
| JP7541064B2 (en) | 2024-08-27 |
| BR112020001755A2 (en) | 2020-07-21 |
| US20230346782A1 (en) | 2023-11-02 |
| EP3658142A4 (en) | 2021-06-09 |
| EP4417260A2 (en) | 2024-08-21 |
| HRP20240840T1 (en) | 2024-10-11 |
| AU2018307964B2 (en) | 2023-11-16 |
| RU2020107188A (en) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269620A (en) | Compositions and methods for treating phenylketonuria | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| HK1256602A1 (en) | Compositions and methods for treating pterygium | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
| IL304820A (en) | Compositions and methods for treating cancer | |
| PT3377516T (en) | Methods and compositions for treating cancer | |
| PT3490582T (en) | Methods and compositions for treating myelofibrosis | |
| IL268684A (en) | Compositions and methods for immunooncology | |
| IL269637A (en) | Compositions and methods for treating synucleinopathies | |
| IL272246A (en) | Compositions and methods for treating galactosemia | |
| IL274837A (en) | Methods and compositions for treating cancers | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| PL3261644T3 (en) | Compositions and methods for treating retinal degradation | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| IL274524A (en) | Compositions and methods for aquaculturing | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| IL269550A (en) | Compositions and methods for treating synucleinopathies | |
| EP3262065C0 (en) | Methods and compositions for treating dystroglycanopathy disorders | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| IL271923A (en) | Methods and compositions for treating addictions | |
| IL272782A (en) | Compositions and methods for treating cancer | |
| HK1250958A1 (en) | Compositions and methods for treating cancer |